Strategic exits Syntheon has a track record of successful exits and asset sales to major players like Medtronic, indicating a potential for collaboration on acquired technologies or co-development opportunities in cardiac and minimally invasive devices.

Innovative legacy With over 200 patents and a history of solving market needs, there is a strong foundation for pitching strategic partnerships, licensing, or joint development programs to expand Syntheon’s product portfolio into adjacent medical device markets.

Fast growth potential Revenue is in the low single digits with recent funding, suggesting ripe opportunity for early-stage strategic customers or investors seeking novel, proven technologies in cardiovascular and related specialties.

Incubator roots Syntheon’s experience as an incubator of technologies later acquired by large firms signals readiness for collaboration on early-stage development projects, pilot programs, and tech transfer engagements.

Strategic partnerships Past investments and partnerships with venture groups and notable medical device firms indicate receptivity to co-development, licensing, and commercialization partnerships with large distributors or OEMs seeking innovative components.